Clinical trial CONTACT 02
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Exelixis |
| EudraCT Identifier | 2020-000348-77 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04446117 |
| Last update |